MedTrace Logo

Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.

NCT00614354 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2013-10-24

No results posted yet for this study

Summary

The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart attack is due to a condition called Acute Coronary Syndrome (ACS). The drug will be injected intravenously. After one or two hours the patient will undergo an imaging procedure to detect if the drug has accumulated in the heart. Uptake of the radioactive drug in the heart is indicative of reduced blood flow to the heart.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

99mTc-glucarate solution

Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Yale University

    collaborator OTHER

  • University of Pittsburgh

    collaborator OTHER

  • University of Alabama at Birmingham

    collaborator OTHER

  • University Hospitals Cleveland Medical Center

    collaborator OTHER

  • Molecular Targeting Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Albert J. Sinusas, MD · Yale University

  • Diwakar Jain, MD · Drexel University

  • Prem Soman, MD, Ph.D. · University of Pittsburgh

  • Ami E Iskandrian, MD · University of Alabama at Birmingham

  • Robert S Jones, MD · University Hospitals Cleveland Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00614354 on ClinicalTrials.gov